Key takeaways
Entyvio (vedolizumab) and Entocort EC (budesonide) are both used to treat Crohn's disease, but they work in different ways and are used for different severities of the condition. Entyvio is a biologic medication known as an integrin antagonist, which is given either as an intravenous infusion or a subcutaneous injection. It is used for moderate-to-severe Crohn's disease and works by reducing the activity of immune cells to lower inflammation. On the other hand, Entocort EC is a corticosteroid taken orally and is used for mild-to-moderate Crohn's disease. It works by reducing inflammation directly in the intestines. Entyvio can cause serious side effects like infusion reactions and infections, while Entocort EC might lead to weight gain, infections, and other steroid-related side effects. Entocort EC is available as a lower-cost generic, whereas Entyvio does not have a generic form.
